Krensavage Asset Management LLC Has $18.15 Million Stake in Abbott Laboratories $ABT

Krensavage Asset Management LLC raised its position in shares of Abbott Laboratories (NYSE:ABT) by 3,900.0% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 200,000 shares of the healthcare product maker’s stock after acquiring an additional 195,000 shares during the period. Abbott Laboratories makes up about 6.9% of Krensavage Asset Management LLC’s investment portfolio, making the stock its 6th largest position. Krensavage Asset Management LLC’s holdings in Abbott Laboratories were worth $18,148,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Plimoth Trust Co. LLC boosted its position in shares of Abbott Laboratories by 2.8% during the second quarter. Plimoth Trust Co. LLC now owns 28,195 shares of the healthcare product maker’s stock valued at $2,558,000 after buying an additional 768 shares during the period. Capital Analysts LLC lifted its stake in shares of Abbott Laboratories by 9.3% during the 2nd quarter. Capital Analysts LLC now owns 126,703 shares of the healthcare product maker’s stock worth $11,497,000 after acquiring an additional 10,819 shares during the last quarter. Concorde Asset Management LLC lifted its stake in shares of Abbott Laboratories by 27.0% during the 2nd quarter. Concorde Asset Management LLC now owns 2,528 shares of the healthcare product maker’s stock worth $229,000 after acquiring an additional 538 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC boosted its holdings in Abbott Laboratories by 11.4% during the 2nd quarter. Pinnacle Wealth Management Advisory Group LLC now owns 6,547 shares of the healthcare product maker’s stock valued at $594,000 after acquiring an additional 668 shares during the period. Finally, NorthRock Partners LLC grew its position in Abbott Laboratories by 3.9% in the 2nd quarter. NorthRock Partners LLC now owns 39,249 shares of the healthcare product maker’s stock valued at $3,561,000 after acquiring an additional 1,464 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s TactiFlex Duo Ablation Catheter, Sensor Enabled, for treating challenging cases of atrial fibrillation. The catheter combines pulsed-field ablation (PFA) and radiofrequency (RF) energy, giving physicians greater flexibility and expanding Abbott’s cardiac rhythm-management portfolio. The device previously received a European CE mark in January 2026, and U.S. approval could support broader adoption and future revenue growth. Abbott’s dual ablation catheter lands FDA approval
• Positive Sentiment: TD Cowen reaffirmed its “buy” rating on Abbott and maintained a $135 price target, indicating substantial potential upside from recent trading levels. The endorsement suggests the firm views Abbott’s product pipeline and long-term fundamentals favorably. TD Cowen reaffirms Abbott buy rating
• Neutral Sentiment: A comparison of Abbott and Envista focuses on which medical-products stock offers better value. Abbott’s established business and growth prospects remain attractive, but its valuation may make it less compelling to investors specifically seeking undervalued shares. NVST or ABT: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Abbott was highlighted as a potential defensive “Dividend King,” supported by a 54-year dividend-growth streak and healthcare-related catalysts. This may appeal to income-focused investors, although the article is general commentary rather than a new company announcement. If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King
• Negative Sentiment: Abbott recently underperformed the broader market in a prior session, reflecting near-term selling pressure. The decline appears market- or sentiment-driven rather than tied to a deterioration in the company’s fundamentals, but it may be tempering the immediate reaction to the FDA news. Here’s Why Abbott Fell More Than the Broader Market

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a report on Thursday, August 13th. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, The Goldman Sachs Group dropped their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $105.29 on Thursday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock’s fifty day moving average price is $105.30 and its 200-day moving average price is $99.90. The firm has a market cap of $182.19 billion, a P/E ratio of 34.07, a P/E/G ratio of 1.96 and a beta of 0.59. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the firm earned $1.26 earnings per share. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.